Objective: The purpose of this study was to determine 1,25-dihydroxyvitamin D 3 [1, 25(OH) 
V
itamin D plays an integral role in bone health, specifically, in calcium and phosphorus homeostasis (1) . Vitamin D deficiency and insufficiency, defined as serum 25-hydroxyvitamin D [25(OH)D] levels Ͻ20 and 21 to 29 ng/mL, respectively, is a major health concern that extends beyond skeletal ailments (2) . Because there is a vitamin D receptor in most every tissue in the body, people of any age or race are at risk of becoming vitamin D deficient (3) (4) (5) . It is an indiscriminate affliction that has been associated with a wide range of health issues such as autoimmune diseases, diabetes, cardiovascular disease, and certain cancers (6 -18) . In a vitamin D-deficient state, the body only absorbs 10% to 15% of dietary calcium and approximately 60% of phosphorus. 1,25-Dihydroxyvitamin D [1, 25(OH) 2 D], the active form of vitamin D, increases the efficiency of intestinal calcium and phosphorus absorption by up to 40% and 80%, respectively (19) .
Humans obtain vitamin D from diet and sunlight (1, 20 -22) . The main source of vitamin D 3 is from exposure to sunlight, accounting for more than 90% of the body's vitamin D requirement (23) . Vitamin D 3 is synthesized in the skin and naturally found in oily fish, whereas vitamin D 2 is present in sundried and UV light-exposed mushrooms (24) . Vitamin D 2 is produced from the irradiation of yeast and vitamin D 3 is produced from lanolin and both are used to fortify milk, other dairy products, orange juice, and cereals (1, 25 (30) . In addition, healthy adults taking 1000 IU vitamin D 2 or 1000 IU vitamin D 3 in a capsule or in orange juice were able to raise their blood level of 25(OH)D to the same level by the end of the 11-week study (31, 32) . Men and women who took 50,000 IU vitamin D 2 twice a month for up to 6 years were able to maintain their serum 25(OH)D at Ͼ30 ng/mL without toxicity (33) .
The purpose of this study was to determine 1,25-dihydroxyvitamin D 3 [1,25( 
Subjects and Methods

Subjects and serum samples
To determine the effect of ingesting 1000 IU vitamin D 2 or 1000 IU vitamin D 3 on circulating blood levels of 1,25(OH) 2 D 2 and 1,25(OH) 2 D 3 and total 1,25(OH) 2 D we evaluated blood samples from a double-blind, placebo-controlled study that was approved by our institutional review board at Boston University Medical Center and published previously (32) . Of the 105 subjects in the parent study, we were able to retrieve the 1 mL of the serum required for the 1,25(OH) 2 A multiplexed analytical HPLC system using a reverse-phase column and reverse-phase gradient was used to effect chromatographic separation. The flow of liquid solvent from the highperformance liquid chromatograph entered a heated nebulizer interface of a LC-MS/MS analyzer (Thermo Fisher Scientific, Waltham, Massachusetts).
Analytes were measured using the selected reaction monitoring mode whereby the mass of the intact analyte was selected in the first quadrupole, collisionally induced dissociation effected in the second quadrupole, and multiple fragment ions sequentially isolated by the third quadrupole.
The areas under the chromatographic peaks were determined, and calibration curves were constructed by plotting standard concentration vs peak area ratio of analyte/internal standard. Using the calibration curves, the concentrations of 1,25(OH) 2 D 2 and 1,25(OH) 2 D 3 were quantitated for patient samples.
The assay has an intraassay coefficient of variation (CV) of 9% and interassay CV of 12%. Serum PTH was determined using immunoassay/spectrophotometry (Quest Diagnostics Nichols Institute, San Juan Capistrano, California). The assay has an intraassay CV of 8% and interassay CV of 10%. 
Statistical analyses
Descriptive statistics (means, medians, and SDs) were computed for baseline and total change at end of the study for each Figure 1 , with change from the first to last visit described in Table 2 Results of longitudinal regression analysis were consistent with these exploratory findings (Table 3) . Compared with placebo, assignment to 1000 IU vitamin D 2 was associated with mean (95% confidence interval) on-treatment increases of 7.4 (4.4 -10.3) pg/mL in 1,25(OH) 2 D 2 accompanied by decreases of similar magnitude in 1,25(OH) 2 D 3 , whereas those assigned to 1000 IU vitamin D 3 exhibited little appreciable change in either parameter. The mean total 25(OH)D increase was greater in those assigned to 1000 IU vitamin D 3 than in those assigned to 1000 IU vitamin D 2 , but evidence in favor of a greater increase associated with 1000 IU vitamin D 3 did not achieve statistical significance when all data were taken into consideration in the longitudinal model (P ϭ .07).
Discussion
Although there continues to be debate as to whether vitamin D 2 is as effective as vitamin D 3 (35) only measured blood levels at 4 and 8 weeks. Furthermore, because they only performed their study in premenopausal women, it is not known whether men and postmenopausal women would also metabolize vitamin D 2 in a manner similar to that of premenopausal women.
In our previous studies, we observed that healthy male and female adults with a wide age range (18 -79 years) who ingested 1000 IU vitamin D 2 or vitamin D 3 in a capsule or in orange juice were able to raise their blood levels of 25(OH)D 2 and 25(OH)D 3 by ϳ10 ng/mL (31, 32) . Furthermore, the groups who received vitamin D 2 demonstrated no significant change in the circulating concentrations of 25(OH)D 3 , and the total blood levels of 25(OH)D were the same whether the adults ingested 1000 IU vitamin D 2 or vitamin D 3 . These blood samples were archived and stored at Ϫ80°C. Because the 1,25(OH) 2 D assay required 1 mL of serum, we recovered 34 samples meeting this requirement; 28.1% were from male participants. The concentrations of 25(OH)D 2 and 25(OH)D 3 gradually increased in a similar fashion over a period of 6 weeks to a plateau level that was sustained for the duration of the trial period. In this analysis, we confirmed that there was no significant difference using our longitudinal model in the increase in serum 25(OH)D 2 for the group who received vitamin D 2 compared with the increase in 25(OH)D 3 in the group who received vitamin D 3 . This was reflected by the observation that the total serum 25(OH)D concentrations were no different for the groups ingesting 1000 IU vitamin D 2 or 1000 IU vitamin D 3 for 11 weeks in this study and the parent studies (31, 32) . However, when only the change from baseline in serum 25(OH)D 2 and 25(OH)D 3 concentrations in this smaller subset of samples from the parent study were compared with the levels at 11 weeks, there was a small, significant (P Ͻ .04) difference with a 2-sample t test. No significant change was observed in the group who received placebo (Figure 1 ).
Serum concentrations of 1,25(OH) 2 D 3 and total 1,25(OH) 2 D did not change throughout the 11 weeks in the adults who ingested 1000 IU vitamin D 3 daily nor in the group who had no additional vitamin D, ie, the placebo group. However, for the group who received 1000 IU vitamin D 2 , there was a gradual increase in the serum concentrations of 1,25(OH) 2 D 2 , which reached a peak concentration at 6 weeks that was sustained for the ensuing 5 weeks and mirrored the increase in the serum 25(OH)D 2 concentrations (Figure 2 ). Although there appeared to be a slight decline in the serum concentrations of 1,25(OH) 2 D 3 , it was not statistically significant, and, furthermore, at the end of 11 weeks, the blood levels were the same as they were at baseline. There was a trend for an increase in total 1,25(OH) 2 D, but the total at baseline (33 Ϯ 2.4 pg/mL) was not statistically significantly different from that at 11 weeks (41.7 Ϯ 3.8 pg/mL). These results add to the initial observation (35) that vitamin D 2 was as effective as vitamin D 3 , not only in Figure 2 . Although this trial was not powered to detect such an increase, it is intriguing to speculate that ingesting vitamin D 2 could potentially increase total circulating concentrations of 1,25(OH) 2 D.
In conclusion, our results demonstrate that vitamin D 2 is metabolized in men and women in a fashion similar to that of vitamin D 3 to both its 25-hydroxy and 1,25-dihydroxy metabolites.
